our busy quarter, to am and Call. XXXX Singular was Good update company's another Earnings pleased welcome Third Quarter I performance. to afternoon, you on Genomics and It
three, execution; execution; the our key following focus areas: and one, update two, commercial innovation X We pipeline. on operational our will
we what I will what what going and well, address is we including of the addition, business, most are state doing importantly, these provide challenges. are differently experiencing challenges In the to overall on commentary
encouraging build path trends, conditions challenges. see have and and Macro directly map clear market the business. GX upfront, successful platform road high last the product to address in a concisely present a To conviction many do we and topic see and
thoughtful strategy our both factors. are in We light internal adapting and being of external in
We QX. are map, commercial about runway includes forward road managing and how structure, organizational business product in This have our to made strategy time give company in to thinking execute. to changes we cash the order
about each in more talk the these will later We call. topics of
Now I'll update on third turn our to quarter. an
Let's progressed academic We X GX which the shipment lab. us start clinical largest with qualified core the sales capability utilization X quarterly of systems leads and the giving yet commercial in pull in book funnel, quarter, increased saw increasing order utilization through and shipments X total to field the X labs the of shipped up GX. made through our and confidence execution. our commercial We during was
to We resonating base the continue customers. the and installed our increasingly flexibility our are growing is our The accuracy of and GX value proposition excited delivering GX power, unmatched customers. with speed, to
sequencing costs that to For our and sequence data." increasing, our flow is long needs time Its addressing extremely our operation. X gave capacity to System very generating and old sequencing color while in instrument us replace streamline pull-through The consumable a but were for reproducible early. purchased still it's Broad single ramp successfully allows a the X Institute equipment, utilization ability and augment cell to libraries the and users. noted instance, chemistry consistently challenge the design difficult new while sequencing us that our "the superb from lower XX-lane was cells
We signs. are and learning encouraging about more initial utilization seeing patterns customer
consumable of kit through growth increasingly in utilization is We be by usability things: over carrying and QX this platform trend QX Consumables X will availability. enabled and believe the revenues more than QX. doubled new early in and higher the
continue usability, and software uptime the improving the significant make reliability the during instrument. to supporting and Regarding upgrades of hardware field we and components quarter, progress of
increased of trend continue. this expect utilization to We
cells. kit newly our new flow the availability, Regarding most of customers over converting currently FX launched are to
reminder, of a As reads the at the doubled from per our providing gigabase. cell lower throughput FX flow higher flow gigabases number significantly FX a cost and cell customers kit a
the kit consumable early In quarter-over-quarter All making ordered sequencing to for addition, to and kits a are things XX% shipped. we for completed and the customers. increase our more access Max than now these Read program single contributed cell number available in of this of broadly
In approximately ramped expected of annualized earliest fact, utilization an last X months placements customer has our X $XXX,XXX. of rate pull-through the over the
in by are in early we translate QX. orders, utilization are which and We these trends encouraged already seeing
to execution. operational Turning
in focus our scaling newly and and launched reliability. the processes consumable streamlining quarter for third GXs cells flow Our usability manufacturing the FX and was enhancing on
operations assay implemented our variability. designed which testing, were manufacturing, intermediate reduce consumables steps In and the processes materials production consumables and quality raw in of consistency we QC component and around and increase to
instrument rolled and and the new of upgrades, several service customer we improve hardware support, features software to and system. In providing usability enhancements out the
launched to kits in cell sequencing. our product for pipeline. single Read Turning Max innovation We
reminder, been benchtop XXX pricing from million to sequencing early designed per up throughput level reads a sell on get feedback single very this kit reads NovaSeq the run. has system. to flow users enables for As positive. billion Recent is and to users This per or access allow X.X cell
Max instrument. data platforms. look adopting to plan libraries single-cell on " sequenced single-cell single-cell data workflow Children's NovaSeq indistinguishable XXx the XXXX. "our GX sequencing to Read analyze our and Nationwide noted of We various compared the interpretation library generated the the to They and instance, from capability For genomics using is the on continue Read GX Max across a forward them Hospital the on
and believe market than -- introducing highly our products offerings, expected. for on unique have new which developing focused become earlier sequencing we previously multiomics finally, our will and spatial a And open we
technology. soon and in exciting We expanding a and look and more this dedicated chemistry development solutions forward of unique in exciting capabilities to area. our We to the leveraging our sharing space, opportunity and this core have this team assays regarding
to Now the I'd our provide on a like few of business. gears and state comments switch overall
a just and macro recent continue a strategy going My what GX over see to on We is we about and platform address despite to what are well have environment. current learned challenges. been touch go-to-market year shipping the challenges what comments our these given progress will doing our for have sequencing we lot
into system read shipments In flow the QX. significant a usability terms over developments more over QX over consumable of seeing growth and well, by Consumables We more given XX% launched reliability in increased in the positive customers will the converting quickly continued increased higher QX. saw and consumables cell We trend FX what FX FX GX. compared are we QX, our a order the QX customers are kits. this flow as in which and revenue is going the to improvements and ASP, kit throughput. doubled and of than have from revenues on time both early We carry Max count cells kits believe utilization impact and Read these has
of We have GX also growing opportunity segment nature clinical the profile. given that conviction the and in the
the and has progressed convert sales of orders opportunities challenges, than cycle to terms slower expected. our to ability In the qualified
over revenue capital and gets acceptance versus line requested of fewer evaluations. delayed instrument. the sales time as result, the has recognized rentals and and pull-through to with reagent a for ramp more has mix models the of the This consumable near-term purchases delivery upfront value As in our shifted opportunities for timing and
will revenue confident trends improvement, funnel we significant our Given we usage, positive pace introductions, placements ordering feel sales product forward. product in the moving customer do new consumables faster and of increased see of reliability system patterns, satisfaction scaling and a
are steps are be this to we taking address this. positive we not increasing point. experiencing following we recognize we at momentum, and While the are we expected where to
growing prioritized consumable up more above installation prepare accelerated across includes This GX GX more the have shipments we organization scale base First, increasing and else. for all demand. effort to focused a a
to our recently and leverage kits. Read is launched FX Second Max
working testing new deliver communications and highlighting also down customers many kits potential on these are double benefits evaluations. as diligently to possible, of We kits outward will and to system the these customers, encouraging sample we as to
the think on time. about are market the robustly on to GX we that kits kits moving product and these forward, differentiate we and competition As focused from profile higher-value bringing
believe conditions Third, as X-pronged product to the needed. challenging ships in strategy in we commercial and address market
be On flexible in side, structure more the deal we will and commercial pricing.
drive We XXXX. through will push conversions. We or significant to this harder believe base downstream growth result on be will deals alternative reagent installation rental the in
differentiated On the leveraging couple a base and product year. much focus The next our significantly ASP. on kits and strategy high-value just differentiated side, installed kits be released new will of carry higher we a will
aforementioned challenges. spending our and We early projects. XX% with more our by the XXXX. believe recently will priorities the resources our a need made prudently reduce in count head the deal and early strategy road on runway narrowly XXXX. more fourth, recognize a to we plans on And accordingly to approximately manage decision into reduced extend product of focused based will cash list and and share our to actions cash difficult these We We map
we plan, our continue As focus attention areas identify potential additional we operating savings. of on our XXXX to cost
value. and always, maximize other we partnerships, strategic stockholder as continue actively to And evaluate opportunities investments to
Now the results. of financial details to the I'll third go through turn our over call quarter to Dalen
